IL12A and neoplasm: One strategy to increase the efficacy of cellular therapy is to combine administration of tumor-specific T cells with interleukin-12 (IL-12), a potent activator of innate and adaptive immunity.11 12 IL-12 is a heterodimeric protein composed of a 35 kDa light chain (p35 or IL-12α) and a 40 kDa heavy chain (p40 or IL-12β) that is mainly produced by phagocytes and dendritic cells.